This study aimed at identifying clinical factors for predicting hematologic toxicity after
radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab in clinical practice …

We retrospectively evaluated our single-center clinical experience with 90Y-ibritumomab
tiuxetan and 131I-tositumomab for therapy of refractory non-Hodgkin's lymphoma (NHL). We …

High-dose 90Y-ibritumomab tiuxetan therapy and associated autologous stem cell
transplantation (ASCT) were applied after dosimetry. This paper reports dosimetric findings …

Ibritumomab tiuxetan is an anti-CD20 murine IgG1 κ monoclonal antibody (ibritumomab)
conjugated to the linker-chelator tiuxetan, which securely chelates 111In for imaging or …

PURPOSE: Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin; IDEC Pharmaceutical, San
Diego, CA) is an effective therapy for patients with relapsed B-cell non-Hodgkin's lymphoma …

This was a 30-patient Phase II trial of reduced-dose 90Y ibritumomab tiuxetan (Zevalin™)
RIT for patients with low-grade, follicular, or transformed B-cell NHL and mild …

Objective: Non-Hodgkin's lymphoma (NHL) is the most frequently diagnosed malignancy of
the immune system, with more than 53,900 new cases diagnosed in 2002. Conventional …

Purpose Positron emission tomography (PET) with 89 Zr-ibritumomab tiuxetan can be used
to monitor biodistribution of 90 Y-ibritumomab tiuxetan as shown in mice. The aim of this …

90Y ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, Cambridge, MA), the first
radioimmunotherapeutic agent approved by the US Food and Drug Administration, is a …

Radioimmunotherapy (RIT) with a commercially available brand of yttrium-90 (90Y)-
ibritumomab-tiuxetan at the prescribed activity of 14.8 MBq/kg (0.4 mCi/kg) represents a …